Matches in SemOpenAlex for { <https://semopenalex.org/work/W2036806957> ?p ?o ?g. }
- W2036806957 endingPage "339" @default.
- W2036806957 startingPage "327" @default.
- W2036806957 abstract "GNE-A (AR00451896; N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide) is a potent, selective MET kinase inhibitor being developed as a potential drug for the treatment of human cancers. Plasma clearance was low in mice and dogs (15.8 and 2.44 mL/min/kg, respectively) and moderate in rats and monkeys (36.6 and 13.9 mL/min/kg, respectively). The volume of distribution ranged from 2.1 to 9.0 L/kg. The mean terminal elimination half-life ranged from 1.67 h in rats to 16.3 h in dogs. Oral bioavailability in rats, mice, monkeys, and dogs were 11.2%, 88.0%, 72.4%, and 55.8%, respectively. Allometric scaling predicted a clearance of 1.3-7.4 mL/min/kg and a volume of distribution of 4.8-11 L/kg in human. Plasma protein binding was high (96.7-99.0% bound). Blood-to-plasma concentration ratios (0.78-1.46) indicated that GNE-A did not preferentially distribute into red blood cells. Transporter studies in MDCKI-MDR1 and MDCKII-Bcrp1 cells suggested that GNE-A is likely a substrate for MDR1 and BCRP. Pharmacokinetic-pharmacodynamic modelling of tumour growth inhibition in MET-amplified EBC-1 human non-small cell lung carcinoma tumour xenograft mice projected oral doses of 5.6 and 13 mg/kg/day for 50% and 90% tumour growth inhibition, respectively. Overall, GNE-A exhibited favourable preclinical properties and projected human dose estimates." @default.
- W2036806957 created "2016-06-24" @default.
- W2036806957 creator A5004172120 @default.
- W2036806957 creator A5005497507 @default.
- W2036806957 creator A5006218365 @default.
- W2036806957 creator A5013314703 @default.
- W2036806957 creator A5035344974 @default.
- W2036806957 creator A5041617519 @default.
- W2036806957 creator A5070894033 @default.
- W2036806957 creator A5087131657 @default.
- W2036806957 creator A5090073956 @default.
- W2036806957 date "2010-12-23" @default.
- W2036806957 modified "2023-10-17" @default.
- W2036806957 title "Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic–pharmacodynamic modelling ofN-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inhibitor" @default.
- W2036806957 cites W1426393029 @default.
- W2036806957 cites W152943885 @default.
- W2036806957 cites W1571923304 @default.
- W2036806957 cites W1979491122 @default.
- W2036806957 cites W1986238320 @default.
- W2036806957 cites W1992009633 @default.
- W2036806957 cites W1998450601 @default.
- W2036806957 cites W1998971866 @default.
- W2036806957 cites W2008345619 @default.
- W2036806957 cites W2018526163 @default.
- W2036806957 cites W2042099048 @default.
- W2036806957 cites W2048097275 @default.
- W2036806957 cites W2055423598 @default.
- W2036806957 cites W2073597573 @default.
- W2036806957 cites W2099474947 @default.
- W2036806957 cites W2107065429 @default.
- W2036806957 cites W2116149669 @default.
- W2036806957 cites W2117750856 @default.
- W2036806957 cites W2119748423 @default.
- W2036806957 cites W2125519805 @default.
- W2036806957 cites W2126922455 @default.
- W2036806957 cites W2136390065 @default.
- W2036806957 cites W2136709806 @default.
- W2036806957 cites W2139438052 @default.
- W2036806957 cites W2155598934 @default.
- W2036806957 cites W2158563134 @default.
- W2036806957 cites W2166182148 @default.
- W2036806957 cites W2169614462 @default.
- W2036806957 cites W2281242723 @default.
- W2036806957 cites W2589957652 @default.
- W2036806957 cites W3009126648 @default.
- W2036806957 doi "https://doi.org/10.3109/00498254.2010.542500" @default.
- W2036806957 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21182395" @default.
- W2036806957 hasPublicationYear "2010" @default.
- W2036806957 type Work @default.
- W2036806957 sameAs 2036806957 @default.
- W2036806957 citedByCount "9" @default.
- W2036806957 countsByYear W20368069572012 @default.
- W2036806957 countsByYear W20368069572013 @default.
- W2036806957 countsByYear W20368069572015 @default.
- W2036806957 countsByYear W20368069572017 @default.
- W2036806957 countsByYear W20368069572019 @default.
- W2036806957 countsByYear W20368069572021 @default.
- W2036806957 crossrefType "journal-article" @default.
- W2036806957 hasAuthorship W2036806957A5004172120 @default.
- W2036806957 hasAuthorship W2036806957A5005497507 @default.
- W2036806957 hasAuthorship W2036806957A5006218365 @default.
- W2036806957 hasAuthorship W2036806957A5013314703 @default.
- W2036806957 hasAuthorship W2036806957A5035344974 @default.
- W2036806957 hasAuthorship W2036806957A5041617519 @default.
- W2036806957 hasAuthorship W2036806957A5070894033 @default.
- W2036806957 hasAuthorship W2036806957A5087131657 @default.
- W2036806957 hasAuthorship W2036806957A5090073956 @default.
- W2036806957 hasConcept C10146269 @default.
- W2036806957 hasConcept C110121322 @default.
- W2036806957 hasConcept C111113717 @default.
- W2036806957 hasConcept C112705442 @default.
- W2036806957 hasConcept C121332964 @default.
- W2036806957 hasConcept C125287762 @default.
- W2036806957 hasConcept C134306372 @default.
- W2036806957 hasConcept C139254425 @default.
- W2036806957 hasConcept C150903083 @default.
- W2036806957 hasConcept C181389837 @default.
- W2036806957 hasConcept C185592680 @default.
- W2036806957 hasConcept C207001950 @default.
- W2036806957 hasConcept C24890656 @default.
- W2036806957 hasConcept C2777056448 @default.
- W2036806957 hasConcept C33923547 @default.
- W2036806957 hasConcept C55493867 @default.
- W2036806957 hasConcept C62231903 @default.
- W2036806957 hasConcept C71924100 @default.
- W2036806957 hasConcept C86803240 @default.
- W2036806957 hasConcept C98274493 @default.
- W2036806957 hasConceptScore W2036806957C10146269 @default.
- W2036806957 hasConceptScore W2036806957C110121322 @default.
- W2036806957 hasConceptScore W2036806957C111113717 @default.
- W2036806957 hasConceptScore W2036806957C112705442 @default.
- W2036806957 hasConceptScore W2036806957C121332964 @default.
- W2036806957 hasConceptScore W2036806957C125287762 @default.
- W2036806957 hasConceptScore W2036806957C134306372 @default.
- W2036806957 hasConceptScore W2036806957C139254425 @default.
- W2036806957 hasConceptScore W2036806957C150903083 @default.
- W2036806957 hasConceptScore W2036806957C181389837 @default.
- W2036806957 hasConceptScore W2036806957C185592680 @default.